uracil-1-beta-D-arabinofuranoside CAS:3083-77-0

Uracil-1-beta-D-arabinofuranoside (ara-U) is an important nucleoside analogue with a modified structure that provides unique biochemical properties. Derived from uracil, the compound features an arabinofuranosyl sugar instead of the typical ribose or deoxyribose, which enhances its solubility and metabolic stability. The presence of the arabinose ring allows ara-U to participate in nucleic acid synthesis, potentially substituting for uridine during RNA synthesis in viral pathogens. The mechanism of action of uracil-1-beta-D-arabinofuranoside primarily involves its incorporation into viral RNA, where it disrupts normal replication processes. By mimicking uridine, ara-U can be incorporated into the growing RNA strand by viral RNA polymerases, leading to termination of elongation or misincorporation events that hinder viral replication. This makes ara-U a promising candidate for targeting various RNA viruses, including those responsible for respiratory and gastrointestinal infections. Research has shown that uracil-1-beta-D-arabinofuranoside exhibits inhibitory effects on several viruses, making it a subject of interest in antiviral drug development. Studies have indicated its effectiveness against human cytomegalovirus (HCMV) and other RNA viruses. Given the continuous emergence of viral diseases and resistance to existing antiviral agents, uracil-1-beta-D-arabinofuranoside holds potential as a therapeutic option. Furthermore, ongoing investigations into the pharmacokinetics and efficacy of ara-U explore its advantages over conventional nucleoside analogs. Its favorable safety profile, coupled with targeted antiviral activity, positions it as a valuable candidate in the search for new antiviral therapies. Overall, uracil-1-beta-D-arabinofuranoside exemplifies the innovative approaches taken in medicinal chemistry to develop effective treatments for viral infections, emphasizing the importance of nucleoside analogs in modern pharmacotherapy.